Home › NDC Lookup › Ingredients › Tadalafil › 00093-3016-65
⚪image loading
(from DailyMed)

Tadalafil 2.5 mg Tablet, Film Coated — NDC 0093-3016-65 (Billing 00093-3016-65)

by Teva Pharmaceuticals USA, Inc. · 2 BLISTER PACK in 1 BOX / 15 TABLET, FILM COATED in 1 BLISTER PACK

This is a package of Tadalafil 2.5 mg Tablet, Film Coated from Teva Pharmaceuticals USA, Inc., no longer marketed (first marketed Aug 2018), no longer in the FDA NDC Directory; retail pharmacies pay about $0.2190 per unit (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00093-3016-65
🏷️ FDA NDC (as labeled) 0093-3016-65 billing pads the labeler segment with a zero
This package
Contains15 tablet, film coated in 1 blister pack Cost per ea$0.2190 NADAC Per package$6.57 / 30 tablets Pack sizes2 compare ↓
Main listing for product 0093-3016 · Also comes in: 483870 tablets 0093-3016-99
Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Tadalafil (different manufacturers) — 3 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 23, 2023 — cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection. (Preferred Pharmaceuticals, Inc.) · FDA recall D-0526-2023
Class II · Mar 16, 2023 — CGMP Deviations (Northwind Pharmaceuticals LLC) · FDA recall D-0553-2023
Class II · Mar 16, 2023 — CGMP Deviations (Northwind Pharmaceuticals LLC) · FDA recall D-0554-2023
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Sep 2025. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-3016-65
Product NDC 0093-3016
11-digit billing NDC 00093301665
NCPDP billing unit EA — each (per item)
SPL Set ID ec80f994-1748-4327-8a4a-887945a3cb4a
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Sep 2025)
Marketing start 2018-08-10
Dosage form TABLET, FILM COATED
Substance TADALAFIL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 40304080000302
GPI class Tadalafil
GCN Seq No 063691
GCN 99409
HICL code 024859
Ingredient (HICL) Tadalafil
HIC1 code F
Therapeutic class — broad (HIC1) Male Genital System
HIC2 code F2
Therapeutic class — intermediate (HIC2) Systemic Fertility Agents
HIC3 code F2A
Therapeutic class — specific (HIC3) Drugs To Treat Erectile Dysfunction (Ed)
AHFS code 24:08.12.00
AHFS class Phosphodiesterase Type 5 Inhibitors
FDB label name TADALAFIL 2.5 MG TABLET
FDB brand name Tadalafil
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 063691
  • GCN: 99409
  • GPI-14 (Medi-Span): 40304080000302
  • HICL (First Databank): 024859
  • AHFS class code: 24:08.12.00
Why two NDCs? The FDA registers this code as 0093-3016-65 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-3016-65. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name TADALAFIL 2.5 MG TABLET Ingredient Tadalafil
📖 What it is MedlinePlus · NLM

Tadalafil (Cialis) is used to treat erectile dysfunction (ED, impotence; inability to get or keep an erection), and the symptoms of benign prostatic hyperplasia (BPH; an enlarged prostate) which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency in adult men. Tadalafil (Adcirca) is used to improve the ability to exercise in people with pulmonary arterial hypertension (PAH; high blood pressure in the vessels carrying blood to the lungs, causing shortness of breath, dizziness, and tiredness). Ta...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Tadalafil is the active ingredient in several branded products, each approved for a specific use. Cialis (and generic tadalafil tablets) treat erectile dysfunction, an enlarged pro...
  • What exactly is tadalafil used for, and why do I see so many different brand names?
  • It depends on what you're taking it for. For erectile dysfunction, your doctor may prescribe it as-needed — taken before sexual activity — or as a lower once-daily dose so you don'...
  • Do I take it every day, or just when I need it?
📖 Read our full Tadalafil guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.219 $6.57 / 30 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Nov 2021 Apr 2022 Sep 2022 Feb 2024 $0.232 $0.144
▲ Up 23% over the last 15 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00093-3016-65 You're viewing this Main listing 2 BLISTER PACK in 1 BOX / 15 TABLET, FILM COATED in 1 BLISTER PACK $0.2190 / ea $6.57 2018-09-27 — Discontinued by firm
00093-3016-99 0093-3016-99 483870 TABLET, FILM COATED in 1 DRUM — — — — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 2 blister pack in 1 box / 15 tablet, film coated in 1 blister pack.
What NDC number is used to bill for this package of Tadalafil 2.5 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Tadalafil 2.5 mg 16714-0074-02 NorthStar 15 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 16729-0369-10 Accord 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 24979-0727-02 Upsher-Smith 500 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 27241-0111-03 Ajanta 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 31722-0643-30 Camber 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 33342-0265-07 Macleods 30 tablets $0.113 AB1 Availability likely save 49%
tadalafil 2.5 mg 35573-0460-56 Burel 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 43547-0030-03 Solco 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 43547-0047-03 Solco 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 43598-0576-30 Dr.Reddys 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 62332-0177-15 Alembic 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 69238-1346-03 Amneal 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 72303-0822-01 HEC 30 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 75834-0247-01 NIVAGEN 1000 tablets $0.113 AB1 Availability likely save 49%
Tadalafil 2.5 mg 47335-0009-64 Sun 15 tablets $0.122 AB1 FDA listed save 44%
Tadalafil 2.5 mgthis 00093-3016-65 Teva 15 tablets $0.219 — Discontinued —
Tadalafil 2.5 mg 13668-0565-05 Torrent 500 tablets — AB1 FDA listed —
tadalafil 2.5 mg 29300-0286-01 Unichem 100 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 35561-0254-10 Bostal 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 42291-0864-30 AvKARE 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 46708-0177-15 Alembic 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 60219-1346-03 Amneal 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 60290-0027-01 Umedica 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 63629-8409-01 Bryant 90 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 65862-0850-30 Aurobindo 30 tablets — — FDA listed —
Tadalafil 2.5 mg 67184-0523-01 Qilu 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 68071-3540-03 NuCare 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 68071-3800-03 NuCare 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 68071-3929-03 NuCare 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 68382-0896-01 Zydus 100 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 70771-1475-00 Zydus 1000 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 71335-1823-01 Bryant 90 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 71335-2363-01 Bryant 90 tablets — AB1 FDA listed —
tadalafil 2.5 mg 71821-0006-01 VKT 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 72865-0104-30 XLCare 30 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 76420-0542-30 Asclemed 15 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 76420-0552-05 Asclemed 500 tablets — AB1 FDA listed —
tadalafil 2.5 mg 76420-0854-01 Asclemed 100 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 82968-0001-03 FOURRTS 15 tablets — AB1 FDA listed —
Tadalafil 2.5 mg 00110-4465-05 Lilly 280000 tablets — — FDA listed —
Tadalafil 2.5 mg 72603-0781-01 NorthStar 1000 tablets — AB1 FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Aug 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Labeler code00093
First marketedAug 2018
Product typeDrug For Further Processing
Portfolio504 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Tadalafil (matched by generic name) — the program that covers self-administered drugs. 21 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Tadalafil. CMS lists 5 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$15.23M
Claims incl. refills
172.4K
Beneficiaries
114.1K
Spend / beneficiary
$133.51
Spend / claim
$88.34
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging No longer marketed (per FDA listing data)

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Teva Pharmaceuticals USA, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 483870 tablets (00093-3016-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00093-3009-93 · Teva 00093-3017-56 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.